Current morbidity and mortality outcomes of cytoreductive surgery with heated intraperitoneal chemotherapy in patients with peritoneal disease: a 5-year retrospective analysis.
2024; Elsevier BV; Volume: 50; Issue: 2 Linguagem: Inglês
10.1016/j.ejso.2023.107873
ISSN1532-2157
AutoresSónia Marques, J. Mendes, Mariana Peyroteo, Mercês Lobo, Fernanda Sousa, Manuel Fernandes, Abreu de Sousa,
Tópico(s)Intraperitoneal and Appendiceal Malignancies
ResumoBackground: Cytoreductive surgery with heated intraperitoneal chemotherapy (CRS-HIPEC) is a well-established treatment for peritoneal carcinomatosis and is associated with increased overall survival. It has been linked to high morbidity rates and routine admission in Intensive care units (ICU) post-operatively, but this has been questioned with the creation of specialized centers. Our aim was to evaluate the morbidity and mortality outcomes and the need for routine ICU admission.
Referência(s)